VivoSeq
Other

Craving

0

Pipeline Programs

0

Active Trials

1

Companies Involved

Craving is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

27

clinical trials

Completed22 · 81%
Terminated2 · 7%
Unknown status2 · 7%
Withdrawn1 · 4%

Trial Activity

27 trials

Cannabidiol and Cocaine Craving/Dependence
Completed··Phase 2·NCT02559167·79 enrolled
Provoked Craving Relief Study by NRT
Completed·GSK logoGSK·Phase 2·NCT01476202·120 enrolled
Provoked Craving Assessment
Completed·GSK logoGSK·Phase 2·NCT01506908·323 enrolled
Endocannabinoids, Stress, Craving And Pain Effects Study
Completed··Phase 1·NCT05480072·12 enrolled
Nicotine Mouth Film for Craving Relief.
Completed·GSK logoGSK·Phase 3·NCT01702532·320 enrolled
Assessment of V0018 2.5 mg Effect on Craving
Completed·PPierre Fabre Medicament·Phase 2·NCT02357888·45 enrolled
Effect of Allopregnanolone on Stress-induced Craving
Completed·YYale University·Phase 1·NCT04015869·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)